S&P 500   3,400.89 (+0.00%)
DOW   27,593.70 (-0.33%)
QQQ   282.63 (+0.77%)
AAPL   116.69 (+1.43%)
MSFT   212.27 (+1.04%)
FB   283.25 (+2.22%)
GOOGL   1,591.38 (+0.45%)
AMZN   3,262.13 (+1.72%)
TSLA   426.70 (+1.53%)
NVDA   536.23 (+2.01%)
BABA   315.58 (+2.84%)
CGC   18.87 (+1.83%)
GE   7.20 (-2.44%)
MU   51.94 (-0.38%)
AMD   80.09 (-2.60%)
T   27.02 (-1.31%)
F   8.01 (-0.25%)
ACB   4.21 (-4.32%)
GILD   59.74 (-0.37%)
NFLX   484.78 (-0.71%)
NIO   27.18 (+4.50%)
BA   157.80 (-1.88%)
DIS   123.98 (-0.06%)
S&P 500   3,400.89 (+0.00%)
DOW   27,593.70 (-0.33%)
QQQ   282.63 (+0.77%)
AAPL   116.69 (+1.43%)
MSFT   212.27 (+1.04%)
FB   283.25 (+2.22%)
GOOGL   1,591.38 (+0.45%)
AMZN   3,262.13 (+1.72%)
TSLA   426.70 (+1.53%)
NVDA   536.23 (+2.01%)
BABA   315.58 (+2.84%)
CGC   18.87 (+1.83%)
GE   7.20 (-2.44%)
MU   51.94 (-0.38%)
AMD   80.09 (-2.60%)
T   27.02 (-1.31%)
F   8.01 (-0.25%)
ACB   4.21 (-4.32%)
GILD   59.74 (-0.37%)
NFLX   484.78 (-0.71%)
NIO   27.18 (+4.50%)
BA   157.80 (-1.88%)
DIS   123.98 (-0.06%)
S&P 500   3,400.89 (+0.00%)
DOW   27,593.70 (-0.33%)
QQQ   282.63 (+0.77%)
AAPL   116.69 (+1.43%)
MSFT   212.27 (+1.04%)
FB   283.25 (+2.22%)
GOOGL   1,591.38 (+0.45%)
AMZN   3,262.13 (+1.72%)
TSLA   426.70 (+1.53%)
NVDA   536.23 (+2.01%)
BABA   315.58 (+2.84%)
CGC   18.87 (+1.83%)
GE   7.20 (-2.44%)
MU   51.94 (-0.38%)
AMD   80.09 (-2.60%)
T   27.02 (-1.31%)
F   8.01 (-0.25%)
ACB   4.21 (-4.32%)
GILD   59.74 (-0.37%)
NFLX   484.78 (-0.71%)
NIO   27.18 (+4.50%)
BA   157.80 (-1.88%)
DIS   123.98 (-0.06%)
S&P 500   3,400.89 (+0.00%)
DOW   27,593.70 (-0.33%)
QQQ   282.63 (+0.77%)
AAPL   116.69 (+1.43%)
MSFT   212.27 (+1.04%)
FB   283.25 (+2.22%)
GOOGL   1,591.38 (+0.45%)
AMZN   3,262.13 (+1.72%)
TSLA   426.70 (+1.53%)
NVDA   536.23 (+2.01%)
BABA   315.58 (+2.84%)
CGC   18.87 (+1.83%)
GE   7.20 (-2.44%)
MU   51.94 (-0.38%)
AMD   80.09 (-2.60%)
T   27.02 (-1.31%)
F   8.01 (-0.25%)
ACB   4.21 (-4.32%)
GILD   59.74 (-0.37%)
NFLX   484.78 (-0.71%)
NIO   27.18 (+4.50%)
BA   157.80 (-1.88%)
DIS   123.98 (-0.06%)
Log in
OTCMKTS:DSNKY

Daiichi Sankyo Stock Forecast, Price & News

$25.56
-0.12 (-0.47 %)
(As of 10/26/2020 12:00 AM ET)
Add
Compare
Today's Range
$25.39
Now: $25.56
$26.00
50-Day Range
$25.68
MA: $69.03
$96.00
52-Week Range
$16.11
Now: $25.56
$33.21
Volume18,883 shs
Average Volume33,314 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, and markets pharmaceutical products worldwide. The company offers prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone compilations; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine and donepezil for treating Alzheimer's disease; laninamivir for anti-influenza treatment; and silodosin for treating dysuria. It also provides olmesartan and Telmisartan antihypertensive agents; levofloxacin, an antibacterial agent; pravastatin and Rosuvastatin antihyperlipidemic agents; iohexol to enhance the visibility of diagnostic X-ray imaging; loxoprofen, an anti-inflammatory analgesic; and naloxegol for opioid-induced constipation treatment. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a cold remedy; Loxonin S, an anti-inflammatory analgesic; Transino for treating melisma/alleviating spots, freckles, and pigmentation; Minon, a moisturizing cleanser; and Clean Dental, an oral care product. Additionally, the company offers Influenza HA Vaccine; Rotarix Oral Liquid, a vaccine for prevention of rotavirus; ActHIB, a haemophilus influenzae type b vaccine; Live Attenuated Measles-Rubella Combined Vaccine; and Squarekids, a vaccine for the prevention of pertussis, diphtheria, tetanus, and poliomyelitis. It also offers pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has a strategic partnership with Ultragenyx Pharmaceutical Inc.; Syneos Health; Thermo Fisher Scientific Inc.; and Gustave Roussy. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceuticals: Other
Sub-IndustryN/A
Current SymbolOTCMKTS:DSNKY
CUSIPN/A
CIKN/A
Phone(136) 225-1111
Employees15,348

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$25.56
-0.12 (-0.47 %)
(As of 10/26/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DSNKY News and Ratings via Email

Sign-up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Daiichi Sankyo (OTCMKTS:DSNKY) Frequently Asked Questions

How has Daiichi Sankyo's stock price been impacted by Coronavirus?

Daiichi Sankyo's stock was trading at $57.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DSNKY stock has decreased by 55.7% and is now trading at $25.56.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Daiichi Sankyo?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daiichi Sankyo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Daiichi Sankyo
.

What guidance has Daiichi Sankyo issued on next quarter's earnings?

Daiichi Sankyo issued an update on its FY 2021 Pre-Market earnings guidance on Friday, July, 31st. The company provided EPS guidance of 0.80-0.80 for the period. The company issued revenue guidance of $9.021-9.021 billion.

Are investors shorting Daiichi Sankyo?

Daiichi Sankyo saw a increase in short interest in September. As of September 30th, there was short interest totaling 12,800 shares, an increase of 77.8% from the September 15th total of 7,200 shares. Based on an average daily volume of 9,800 shares, the short-interest ratio is presently 1.3 days.
View Daiichi Sankyo's Short Interest
.

Who are some of Daiichi Sankyo's key competitors?

Who are Daiichi Sankyo's key executives?

Daiichi Sankyo's management team includes the following people:
  • Mr. Sunao Manabe, Pres, Group CEO & Representative Director (Age 66)
  • Mr. Toshiaki Sai, CFO, Exec. VP, Head of Corp. Strategy & Management Division and Representative Director
  • Mr. Naoki Hatakeyama, Sr. Director of Compliance Group, Legal Affairs Department & Corp. Affairs Division
  • Mr. Junichi Onuma, VP of Corp. Communications Department
  • Mr. Satoru Kimura, Head of Sales & Marketing Division, Sr. Exec. Officer and Director (Age 63)

What is Daiichi Sankyo's stock symbol?

Daiichi Sankyo trades on the OTCMKTS under the ticker symbol "DSNKY."

How do I buy shares of Daiichi Sankyo?

Shares of DSNKY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Daiichi Sankyo's stock price today?

One share of DSNKY stock can currently be purchased for approximately $25.56.

What is Daiichi Sankyo's official website?

The official website for Daiichi Sankyo is www.daiichisankyo.com.

How can I contact Daiichi Sankyo?

The company can be reached via phone at (136) 225-1111.

This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.